cbdMD, Inc. Price & Performance (YCBD)

cbdMD shareholders have authorized the automatic conversion of Series A Preferred Stock into common shares and a one-for-eight reverse stock split, effective May 6. These moves will remove $10.7 million in dividend obligations, streamline the capital structure, and support NYSE American listing compliance, positioning the company for future growth and acquisitions.1234

cbdMD’s proprietary CBD isolate has advanced to the final phase of the UK Food Standards Agency’s novel food approval process. The positive safety assessment marks an important step toward full authorization, potentially giving cbdMD a competitive edge in the £800 million UK CBD market as regulatory clarity drives consumer trust and market share.56

cbdMD reported $5.1 million in revenue for Q1 FY2025, a 12% sequential rise, and its first-ever positive adjusted EBITDA. The company has become debt-free after converting remaining notes and is focusing on expanding distribution for its new THC-infused beverage, Herbal Oasis, as it pursues profitable growth.2